[go: up one dir, main page]

CO2017002472A2 - Formulación de acetato de abiraterona - Google Patents

Formulación de acetato de abiraterona

Info

Publication number
CO2017002472A2
CO2017002472A2 CONC2017/0002472A CO2017002472A CO2017002472A2 CO 2017002472 A2 CO2017002472 A2 CO 2017002472A2 CO 2017002472 A CO2017002472 A CO 2017002472A CO 2017002472 A2 CO2017002472 A2 CO 2017002472A2
Authority
CO
Colombia
Prior art keywords
abiraterone acetate
acetate formulation
formulation
compositions
producing
Prior art date
Application number
CONC2017/0002472A
Other languages
English (en)
Spanish (es)
Inventor
Maura Murphy
Paul Nemeth
H William Bosch
Matthew Callahan
Satya Bhamidipati
Jason Coleman
Christopher Hill
Marck Norret
Original Assignee
Iceutica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55533897&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2017002472(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US14/707,922 external-priority patent/US20150246060A1/en
Application filed by Iceutica Inc filed Critical Iceutica Inc
Publication of CO2017002472A2 publication Critical patent/CO2017002472A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)
CONC2017/0002472A 2014-09-18 2017-03-15 Formulación de acetato de abiraterona CO2017002472A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462052294P 2014-09-18 2014-09-18
US14/707,922 US20150246060A1 (en) 2013-03-15 2015-05-08 Abiraterone Acetate Formulation and Methods of Use
PCT/US2015/050889 WO2016044701A1 (fr) 2014-09-18 2015-09-18 Formulation d'acétate d'abiratérone et ses procédés d'utilisation

Publications (1)

Publication Number Publication Date
CO2017002472A2 true CO2017002472A2 (es) 2017-07-11

Family

ID=55533897

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0002472A CO2017002472A2 (es) 2014-09-18 2017-03-15 Formulación de acetato de abiraterona

Country Status (17)

Country Link
EP (1) EP3193857A4 (fr)
JP (1) JP2017528457A (fr)
KR (2) KR102491439B1 (fr)
CN (1) CN106687112A (fr)
AP (1) AP2017009804A0 (fr)
AU (1) AU2015317466A1 (fr)
BR (1) BR112017003219A2 (fr)
CA (1) CA2958316A1 (fr)
CO (1) CO2017002472A2 (fr)
EA (1) EA201790650A1 (fr)
IL (1) IL250270B (fr)
MD (1) MD20170048A2 (fr)
MX (1) MX2017003525A (fr)
PH (1) PH12017500239A1 (fr)
SG (1) SG11201701139YA (fr)
TN (2) TN2017000098A1 (fr)
WO (1) WO2016044701A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3824908A1 (fr) 2015-04-10 2021-05-26 Capsugel Belgium NV Formulations lipidiques d'acétate d'abiratérone
CN110891549A (zh) * 2017-04-07 2020-03-17 玛亚实验室公司 改善治疗剂的溶解度和生物利用度的方法
EP3914234A4 (fr) * 2019-01-25 2022-09-14 Shenzhen Pharmacin Co., Ltd. Compositions pharmaceutiques
JP7644713B2 (ja) 2019-03-06 2025-03-12 プロペラ セラピューティクス インコーポレイテッド アビラテロンプロドラッグ
CN110742870B (zh) * 2019-12-04 2021-04-20 武汉大学 醋酸阿比特龙制剂及其制备方法
CN111110646A (zh) * 2020-02-19 2020-05-08 纳兰迦(上海)生物医药科技有限公司 一种低规格醋酸阿比特龙口服制剂的处方及制备方法
CN113384542B (zh) * 2020-03-14 2024-03-29 鲁南制药集团股份有限公司 一种甾体cyp17抑制剂固体分散体的片剂及其制备方法
CA3175658A1 (fr) * 2020-04-16 2021-10-21 Richard Balazs Karpati Procedes et compositions de traitement du cancer de la prostate
WO2021224471A1 (fr) * 2020-05-08 2021-11-11 Janssen Pharmaceutica Nv Formulations pharmaceutiques d'acétate d'abiratérone et de niraparib
EP3944860A1 (fr) 2020-07-30 2022-02-02 Galenicum Health S.L.U. Abiratérone pour utilisation dans un procédé de traitement du cancer
EP4291159A1 (fr) 2021-02-15 2023-12-20 Propella Therapeutics, Inc. Promédicaments d'abiratérone
KR20240044329A (ko) 2022-09-28 2024-04-04 한미약품 주식회사 아비라테론 아세테이트 및 프레드니솔론을 포함하는 경구용 복합정제
KR20240145412A (ko) 2023-03-27 2024-10-07 한미약품 주식회사 아비라테론 아세테이트 및 프레드니솔론을 포함하는 약제학적 제제 및 이의 제조방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG175765A1 (en) * 2009-04-24 2011-12-29 Iceutica Pty Ltd Production of encapsulated nanoparticles at commercial scale
GB201207886D0 (en) * 2012-05-04 2012-06-20 Jagotec Ag Improvements in or relating to organic compounds
WO2014009434A1 (fr) * 2012-07-11 2014-01-16 Sandoz Ag Système d'administration de médicament auto-microémulsifiant à base d'abiratérone ou d'acétate d'abiratérone
WO2014009436A1 (fr) 2012-07-11 2014-01-16 Sandoz Ag Nanosuspension d'acétate d'abiratérone
WO2014009437A1 (fr) * 2012-07-11 2014-01-16 Sandoz Ag Stabilité d'oxydation d'acétate d'abiratérone
CN102743393A (zh) 2012-07-27 2012-10-24 海南盛科生命科学研究院 一种含有醋酸阿比特龙的药物组合物及制备工艺
RU2732136C2 (ru) * 2013-03-15 2020-09-11 Айсьютика Инк. Состав на основе абиратерона ацетата

Also Published As

Publication number Publication date
AP2017009804A0 (en) 2017-03-31
IL250270A0 (en) 2017-03-30
CN106687112A (zh) 2017-05-17
EP3193857A4 (fr) 2018-04-11
CA2958316A1 (fr) 2016-03-24
SG11201701139YA (en) 2017-03-30
EP3193857A1 (fr) 2017-07-26
TN2018000318A1 (en) 2020-01-16
KR20230014878A (ko) 2023-01-30
IL250270B (en) 2021-02-28
KR102617537B1 (ko) 2023-12-22
EA201790650A1 (ru) 2017-07-31
KR20170070025A (ko) 2017-06-21
JP2017528457A (ja) 2017-09-28
BR112017003219A2 (pt) 2017-11-28
TN2017000098A1 (en) 2018-10-19
PH12017500239A1 (en) 2017-07-03
WO2016044701A1 (fr) 2016-03-24
MD20170048A2 (ro) 2017-08-31
KR102491439B1 (ko) 2023-01-25
MX2017003525A (es) 2017-06-21
AU2015317466A1 (en) 2017-02-23

Similar Documents

Publication Publication Date Title
CO2017002472A2 (es) Formulación de acetato de abiraterona
ZA202004557B (en) Modulatory polynucleotides
BR112015023629A8 (pt) Formulação de acetato de abiraterona
CL2016002772A1 (es) Composiciones de insulina de rápida acción
NI201600071A (es) Compuestos de inhibidor de autotaxina
CL2016001609A1 (es) Composiciones farmacéuticas que comprenden azd9291.
HK1218621A1 (zh) 用於治疗慢性炎症和炎性疾病的组合物及方法
MX2015012833A (es) Composiciones antibioticas de ceftolozano.
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
BR112017001221A2 (pt) derivados de indolizina que são aplicáveis a doenças neurodegenerativas
SV2017005412A (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
CR20170090A (es) Derivados de terahidroquinolina como inhibidores del bromodominio
EP3149035A4 (fr) Compositions thérapeutiques comprenant de petites molécules thérapeutiques et leurs utilisations
MX2017000676A (es) Oritavancina de alta pureza y metodo para producir la misma.
MX2016012784A (es) Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones.
WO2014107596A8 (fr) Compositions et procédés de transfection de polynucléotides
GT201600252A (es) Derivados de naftiridinadiona
MX2017009827A (es) Formulacion farmaceutica.
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
MX2015016603A (es) Composiciones de corticosteroides.
BR112017024126A2 (pt) composições farmacêuticas e uso das mesmas
GT201600190A (es) Compuestos químicos
BR112018010211A2 (pt) formulação farmacêutica aquosa compreendendo anticorpo anti-pd-l1 avelumab
UA106905U (uk) Фармацевтична композиція
MX2016001694A (es) Formulacion de vacuna de sacarido.